China holds all the cards in global pharmaceuticals despite India’s bid to reshuffle the deck

China's dominance over raw materials for medicines presents a significant supply-chain vulnerability for the US. A US commission urges Congress to require pharmaceutical firms to report supply chain origins and encourage diversification away from China, highlighting the risks of over-reliance on a geopolitical rival.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K5BSoNt
via IFTTT